Effect of the market withdrawal of carisoprodol on use of other prescribed drugs with abuse potential

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 3, 2012, Pages 438-441

  Bramness, J G ^a,b   Furu, K ^a,c   Skurtveit, S ^a,b   Engeland, A ^a,d  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CARISOPRODOL; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANALGESIA; ARTICLE; DRUG ABUSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW BACK PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NORWAY; PRESCRIPTION; PRIORITY JOURNAL;

BEHAVIOR, ADDICTIVE; CARISOPRODOL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; NORWAY; SAFETY-BASED DRUG WITHDRAWALS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84857238235     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.250     Document Type: Article

References (22)

1. EMEA. Scientific conclusions: overall summary of the scientific evaluation of medicinal products containing carisoprodol. Appendix I 〈http://www ema europa.eu/docs/en-GB/document-library/Referrals-document/ carisoprodol-107/WC500012425 pdf〉 (2007).
2. Fass, J.A. Carisoprodol legal status and patterns of abuse. Ann. Pharmacother. 44, 1962-1967 (2010).
3. Reeves, R.R., Pinkofsky, H.B. & Carter, O.S. Carisoprodol: a drug of continuing abuse. J. Am. Osteopath. Assoc. 97, 723-724 (1997). (Pubitemid 28016595)
4. Bailey, D.N. & Briggs, J.R. Carisoprodol: an unrecognized drug of abuse. Am. J. Clin. Pathol. 117, 396-400 (2002). (Pubitemid 34226074)
5. Heacock, C. & Bauer, M.S. Tolerance and dependence risk with the use of carisoprodol. Am. Fam. Physician 69, 1622-1623 (2004). (Pubitemid 38469230)
6. Owens, C. et al. Abuse potential of carisoprodol: a retrospective review of Idaho Medicaid pharmacy and medical claims data. Clin. Ther. 29, 2222-2225 (2007). (Pubitemid 350138561)
7. Forrester, M.B. Carisoprodol abuse in Texas, 1998-2003. J Med Toxicol. 2, 8-13 (2006).
8. Bramness, J.G., Furu, K., Engeland, A. & Skurtveit, S. Carisoprodol use and abuse in Norway: a pharmacoepidemiological study. Br. J. Clin. Pharmacol. 64, 210-218 (2007). (Pubitemid 47063238)
9. Bramness, J.G., Skurtveit, S., Mørland, J. & Engeland, A. The risk of traffic accidents after prescriptions of carisoprodol. Accid. Anal. Prev. 39, 1050-1055 (2007). (Pubitemid 47381351)
10. Bramness, J.G., Skurtveit, S. & Mørland, J. Impairment due to intake of carisoprodol. Drug Alcohol Depend. 74, 311-318 (2004). (Pubitemid 38759786)
11. Adams, H.R., Kerzee, T. & Morehead, C.D. Carisoprodol-related death in a child. J. Forensic Sci. 20, 200-202 (1975).
12. Roth, B.A., Vinson, D.R. & Kim, S. Carisoprodol-induced myoclonic encephalopathy. J. Toxicol. Clin. Toxicol. 36, 609-612 (1998). (Pubitemid 28460674)
13. Siddiqi, M. & Jennings, C.A. A near-fatal overdose of carisoprodol (SOMA): case report. J. Toxicol. Clin. Toxicol. 42, 239-240 (2004). (Pubitemid 38758537)
14. Backer, R.C., Zumwalt, R., McFeeley, P., Veasey, S. & Wohlenberg, N. Carisoprodol concentrations from different anatomical sites: three overdose cases. J. Anal. Toxicol. 14, 332-334 (1990). (Pubitemid 20324460)
15. Bramness, J.G., Buajordet, I.& Skurtveit, S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe. Nor J Epidemiol 18, 167-172 (2008). (Pubitemid 351859940)
16. European Medicines Agency. Press release. European Medicines Agency recommends suspension of marketing authorisations for carisoprodolcontaining medicinal products 〈http://www.ema.europa.eu/docs/en-GB/document-library/ Press-release/2009/11/WC500015582 pdf〉 (2007).
17. US Department of Justice Drug Enforcement Administration. Federal Register Notices 〈http://www.deadiversion.usdoj.gov/fed-regs/index. html〉. Rules 2009 〈http://www.deadiversion.usdoj.gov/fed-regs/rules/ 2009/index. html〉. Placement of Carisoprodol into Schedule IV. November 10 2009 〈http://www.deadiversion.usdoj.gov/fed-regs/rules/2009/fr1117. htm〉.
18. Furu, K., Wettermark, B., Andersen, M., Martikainen, J.E., Almarsdottir, A.B. & Sørensen, H.T. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin. Pharmacol. Toxicol. 106, 86-94 (2010).
19. Reeves, R.R. & Burke, R.S. Is it time for carisoprodol to become a controlled substance at the federal level? South. Med. J. 101, 127-128 (2008).
20. H øiseth, G., Karinen, R., Sørlid, H.K. & Bramness, J.G. The effect of scheduling and withdrawal of carisoprodol on prevalence of intoxications with the drug. Basic Clin. Pharmacol. Toxicol. 105, 345-349 (2009).
21. Furu, K. Establishment of the nationwide Norwegian Prescription Database (NorPD)-new opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 18, 129-136 (2008). (Pubitemid 351859935)
22. World HealtHorganization Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. Guidelines for ATC classification and DDD assignment. Oslo, Norway (2009).